Analyst Ratings For Axovant Sciences Ltd (NASDAQ:AXON)
Today, HC Wainwright reiterated its Buy rating on Axovant Sciences Ltd (NASDAQ:AXON) with a price target of $7.00.
There are 7 Hold Ratings, 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Axovant Sciences Ltd (NASDAQ:AXON) is Hold with a consensus target price of $12.6667 per share, a potential 511.92% upside.
Some recent analyst ratings include
- 8/13/2018-Axovant Sciences Ltd (NASDAQ:AXON) had its Buy rating reiterated by HC Wainwright with a $7.00 price target
- 7/9/2018-Axovant Sciences Ltd (NASDAQ:AXON) had its Hold rating reiterated by Oppenheimer
- 6/6/2018-Axovant Sciences Ltd (NASDAQ:AXON) had its Hold rating reiterated by Chardan Capital with a $4.00 price target
- 2/13/2018-Axovant Sciences Ltd (NASDAQ:AXON) had its Hold rating reiterated by Cowen
- 11/10/2017-Axovant Sciences Ltd (NASDAQ:AXON) had its Hold rating reiterated by Piper Jaffray Companies
- 11/1/2017-Axovant Sciences Ltd (NASDAQ:AXON) had its Hold rating reiterated by Robert W. Baird with a $6.00 price target
Recent Insider Trading Activity For Axovant Sciences Ltd (NASDAQ:AXON)
Axovant Sciences Ltd (NASDAQ:AXON) has insider ownership of 6.00% and institutional ownership of 13.94%.
- On 6/5/2018 Global Investors Lp Viking, Major Shareholder, bought 14,285,714 with an average share price of $1.75 per share and the total transaction amounting to $24,999,999.50.
- On 2/27/2018 George Bickerstaff, Director, bought 25,000 with an average share price of $1.50 per share and the total transaction amounting to $37,500.00.
- On 4/17/2017 David Hung, Insider, bought 539,375 with an average share price of $18.54 per share and the total transaction amounting to $10,000,012.50.
- On 4/17/2017 W Anthony Vernon, Director, bought 53,937 with an average share price of $18.54 per share and the total transaction amounting to $999,991.98.
- On 3/10/2016 Mark Altmeyer, Insider, bought 2,300 with an average share price of $11.14 per share and the total transaction amounting to $25,622.00.
About Axovant Sciences Ltd (NASDAQ:AXON)
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Recent Trading Activity for Axovant Sciences Ltd (NASDAQ:AXON)
Shares of Axovant Sciences Ltd closed the previous trading session at 2,07 +0,030 1,47 % with 2.12 shares trading hands.
